Toward a molecular neuropsychiatry of neurodegenerative diseases

Annals of Neurology

Volumn 54, Issue 2, 2003, Pages 147-154

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BRAIN PROTEIN; HUNTINGTIN; PEPTIDE; PRION PROTEIN; SUPEROXIDE DISMUTASE; TAU PROTEIN; UBIQUITIN;

ALZHEIMER DISEASE; APATHY; BEHAVIOR DISORDER; BEHAVIORAL SCIENCE; BRAIN DEGENERATION; COMPULSION; DEGENERATIVE DISEASE; DELUSION; DEMENTIA; DISEASE ASSOCIATION; FUNCTIONAL ANATOMY; HALLUCINATION; HUMAN; HYPERPHOSPHORYLATION; METABOLIC DISORDER; METABOLIC REGULATION; MOLECULAR BIOLOGY; NEUROANATOMY; NEUROPSYCHIATRY; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; QUANTITATIVE DIAGNOSIS; REGULATORY MECHANISM; REM SLEEP; REVIEW; SYMPTOMATOLOGY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; BIOLOGICAL PSYCHIATRY; GENOTYPE; HUMANS; NERVE TISSUE PROTEINS; NEUROBIOLOGY; NEURODEGENERATIVE DISEASES; PHENOTYPE; SYNUCLEINS;

EID: 0042344905     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10616     Document Type: Review

References (92)

1. Cummings JL. The neuropsychiatry of Alzheimer's disease and related dementias. London: Martin Dunitz, 2002.
2. Lovestone S, McLoughlin DM. Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry 2002;72:152-161.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
5. Galvin J, Lee VM-Y, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-190.
6. Dickson D. α-Synuclein and the Lewy body disorders. Curr Opin Neurol 2001;14:423-432.
7. Hong M, Trojanowski JQ, Lee VM-Y. Tau-based neurofibrillary lesions. In: Clark CM, Trojanowski JQ, eds. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000:161-175.
8. McKhann G, Albert M, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia. Arch Neurol 2001;58:1803-1809.
9. Perl DP. Amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. In: Markesbery WR, ed. Neuropathology of dementing disorders. New York: Arnold, 1998:268-292.
10. Prusiner SB. Shattuck lecture-neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-1526.
11. Beal MF. A gain of function of the Huntington's disease and amyotrophic lateral sclerosis-associated genetic mutations may be a loss of bioenergetics. In: Beyreuther K, Christen Y, Masters CL, eds. Neurodegenerative disorders. Berlin: Springer-Verlag, 2001:173-185.
12. Harper PS. Huntington's disease: a clinical, genetic, and molecular model for polyglutamine repeat disorders. In: Harper P, Perutz M, eds. Glutamine repeats and neurodegenerative diseases: molecular aspects. New York: Oxford University Press, 2001:1-9.
13. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-1995.
14. Golbe LI. Neurodegeneration in the age of molecular biology. Br Med J 2002;324:1467-1468.
15. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteosome system by protein aggregation. Science 2001;292:1552-1555.
16. Spillantini MG, Schimdt ML, Lee VM-Y, et al. α-Synuclein in Lewy bodies. Nature 1997;388:839-840.
17. Gomez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-1291.
18. Braak H, De Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
19. Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55:1454-1456.
20. Forloni G, Bertani I, Calella AM, et al. α-Synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 2000;47:632-640.
21. Markesbery WR, Montine TJ, Lovell MA. Oxidative alterations in neurodegenerative disorders. In: Mattson MP, ed. Pathogenesis of neurodegenerative disorders. Totowa, NJ: Humana Press, 2001:21-51.
22. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev 2002;3:1-11.
23. Litvan I, Mohr E, Williams J, et al. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1991;54:25-29.
24. Gabrieli JDE, Singh J, Stebbins GT, Goetz CG. Reduced working memory span in Parkinson's disease: evidence for the role of a frontostriatal system in working and strategic memory. Neuropsychology 1996;10:322-332.
25. Appollonio I, Grafman J, Clark K, et al. Implicit and explicit memory in patients with Parkinson's disease with and without dementia. Arch Neurol 1994;51:359-367.
26. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992;49:492-497.
27. Aarsland D, Tandberg E, Larsen JP, Cummings J. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538-542.
28. Apaydin H, Ahlskog E, Parisi JE, et al. Parkinson disease neuropathology. Arch Neurol 2002;59:102-112.
29. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496.
30. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:184-191.
31. Sanchez-Ramos J, Ortoll R, Paulson G. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-1268.
32. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
33. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-2082.
34. Ondo WG, Vuong KD, Khan H, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-1396.
35. Hobson DE, Lang AE, Wayne Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. JAMA 2002;287:455-463.
36. Comella C, Nardine T, Diedrich N, Stebbins G. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998;51:526-529.
37. Gagnon J-F, Bedard M-A, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.
38. Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999;156:1039-1045.
39. Ferman TJ, Boeve BF, Smith GE, et al. REM sleep behavior disorder and dementia: cognitive differences when compared with AD. Neurology 1999;52:951-957.
40. Hirono N, Mori E, Tanimukai S, et al. Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci 1999;11:498-503.
41. Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 1987;6:193-208.
42. Zhukareva V, Vogelsberg-Ragaglia V, Van Deerlin VMD, et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol 2001;49:165-175.
43. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
44. Foster NL, Wilhemsen K, Sima AFS, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997;41:706-715.
45. Goedert M, Spillantini MG. Tauopathies and α-synucleinopathies. In: Lee V, Trojanowski JQ, Buee L, Christen Y, eds. Fatal attractions: aggregates in neurodegenerative disorders. Berlin: Springer-Verlag, 2000:65-86.
46. Buee L, Mailliot C, Bussiere T, et al. Neurodegenerative disorders with tauopathies: mad tau diseases? In: Lee V, Trojanowski JQ, Buee L, Christen Y, eds. Fatal attractions: protein aggregates in neurodegenerative disorders. Berlin: Springer-Verlag, 2000:105-125.
47. Mandelkow E-M, Biernat J, Ebneth A, et al. Tau protein: role in intracellular traffic and development of cell polarity. In: Lee V, Trojanowski JQ, Buee L, Christen Y, eds. Fatal attractions: protein aggregates in neurodegenerative disorders. Berlin: Springer-Verlag, 2000:127-138.
48. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873-880.
49. Levy ML, Miller BL, Cummings JL, et al. Alzheimer disease and frontotemporal dementias: behavioral distinctions. Arch Neurol 1996;53:687-690.
50. Miller BL, Darby A, Benson DF, et al. Agressive, socially, disruptive and antisocial behavior associated with frontotemporal dementia. Br J Psychiatry 1997;170:150-155.
51. Miller BL, Seeley WW, Mychack P, et al. Neuroanatomy of the self: evidence from patients with frontotemporal dementia. Neurology 2001;57:817-821.
52. Snowden J, Bathgate D, Varma A, et al. Distinct behavioural profiles in fronototemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 2001;70:323-332.
53. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47:1184-1189.
54. Litvan I, Cummings J, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717-721.
55. Arciniegas DB, Beresford TP. Neuropsychiatry: an introductory approach. Cambridge, UK: Cambridge University Press, 2001.
56. Ames D, Cummings JL, Wirshing WC, et al. Repetitive and compulsive behavior in frontal lobe degenerations. J Neuropsychiatry Clin Neurosci 1994;6:100-113.
57. Mendez MF, Perryman KM, Miller BL, et al. Compulsive behaviors as presenting symptoms of frontotemporal dementia. J Geriatr Psychiatry Neurol 1997;10:154-157.
58. Brookes AJ, St. Clair D. Synuclein proteins and Alzheimer's disease. Trends Neurosci 1994;17:404-405.
59. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378-384.
60. Trojanowski JQ. Tauists, baptists, syners, apostates, and new data. Ann Neurol 2002;52:263-264.
61. Beyreuther K, Masters CL. Alzheimer's disease: physiological and pathogenetic role of the amyloid precursor protein (APP), its α-beta-amyloid domain and free α-beta-amyloid peptide. In: Beyreuther K, Christen Y, Masters CL, eds. Neurodegenerative disorders: loss of function through gain of function. Berlin: Springer-Verlag, 2001:97-117.
62. Yang L-B, Lindholm K, Yan R, et al. Elevated B-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003;9:3-7.
63. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain AB by neprilysin. Science 2001;292:1550-1552.
64. Hauw J-J, Duyckaerts C, Delaere P, Piette F. Topography of lesions in Alzheimer's disease: a challenge to morphologists. In: Rapoport SR, Petit H, Leys D, Christen Y, eds. Imaging, cerebral topography and Alzheimer's disease. Berlin: Alle Zeit Wach, 1990.
65. Gomez-Isla T, Hyman BT. Connections and cognitive impairment in Alzheimer's disease. In: Hyman B, Duyckaerts C, Christen Y, eds. Connections, cognition, and Alzheimer's disease. Berlin: Springer-Verlag, 1997:149-166.
66. Thal DR, Rüb U, Orantes M, Braak H. Phases of AB-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
67. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer's disease. Arch Neurol 1999;56:1233-1239.
68. Tekin S, Mega MS, Masterman DL, et al. Orbitofrontal and anterior cingulate cortex: neurofibrillary tangle burden is associated with agitation in Alzheimer's disease. Ann Neurol 2001;49:355-361.
69. Braak H, Griffing K, Braak E. Review article: neuroanatomy of Alzheimer's disease. Alzheimer Res 1997;3:235-247.
70. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51:S2-S17.
71. Bondi MW, Salmon DP, Kaszniak AW. The neuropsychology of dementia. In: Grant I, Adams KM, eds. Neuropsychological assessment of neuropsychiatric disorders. New York: Oxford University Press, 1996:164-199.
72. Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurological basis. Response to commentaries. Neurobiol Aging 2000;21:845-861.
73. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
74. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:42-49.
75. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54:1965-1971.
76. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985;35:453-461.
77. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-681.
78. Caliguri MP, Peavy G. An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000;12:34-39.
79. Galvin JE, Lee SL, Perry A, et al. Familial dementia with Lewy bodies. Neurology 2002;59:1079-1082.
80. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
81. Hardy J, Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science 1998;282:1075-1079.
82. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-1706.
83. Sobrido MJ, Abu-Khalil A, Weintraub S, et al. Possible association of the tau H1/H1 genotype with primary progressive aphasia. Neurology 2003;60:862-864.
84. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
85. Bruton CJ. Head injury and dementia. In: Esiri MM, Morris JH, eds. The neuropathology of dementia. Cambridge: Cambridge University Press, 1997:344-356.
86. Simuni TA, Hurtig HI. Parkinson's disease: the clinical picture. In: Clark CM, Trojanowski JQ, eds. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000:193-203.
87. Cheyette S, Cummings JL. Encephalitis lethargica: lessons for contemporary neuropsychiatry. Neuropsychiatry Clin Neurosci 1995;7:125-134.
88. Corsellis JAN, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med 1973;3:270-303.
89. Tsuang DW, Dalan AM, Eugenio CJ, et al. Familial dementia with Lewy bodies. Arch Neurol 2002;59:1622-1630.
90. Levy ML, Cummings JL, Fairbanks LA, et al. Apolipoprotein E genotype and non-cognitive symptoms in Alzheimer's disease. Biol Psychiatry 1999;45:422-425.
91. Wolfe MS, Esler WP, Das C. Continuing strategies for inhibiting Alzheimer's gamma-secretase. J Mol Neurosci 2002;19:83-87.
92. Iqbal K, Alonso ADC, El-Akkad E, et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J Mol Neurosci 2002;19:95-99.